Dong Xie, PhD

Founder, Chairman, CSO

PhD John Hopkins Univ.

Executive Director Biocalorimetry Center at John Hopkins; Director Biophysics Lab at National Cancer Institute/NIH

Global Project Leader and R&D Director at Tibotec (acquired by J&J), led three novel anti-HIV drug development

CJ Wang, PhD

Board Director, CEO

PhD College of Pharmacy, Univ. of Kentucky 

>20+ years R&D and business development experience in US

VP BD at Vivus (Nasdaq: VVUS), Abmaxis (acquired by Merck) and TaiGen Biotech; VP Marketing and BD at Cellomics; Director BD and M&A at Packard Bioscience; Principal Scientist at Merck

RJ Lu, PhD

Board Director, CTO

PhD Nankai Univ., Postdoc Northeastern Univ. / Harvard Medical School; Sr. postdoctoral fellow at NCI 

Principal Research Investigator / Project Leader at Sequoia and Trimeris; Senior Scientist at Tibotec

Led and participated in CMC development of several anti-HIV drugs including T-20 and Darunavir>

Michelle Zheng PhD

CQO

PhD Western Ontario Univ.

Pharmaceutical executive with 24+ years experience in drug development, CMC, Quality and management at MabPlex, Adellos, Omeros, and AbbVie

Michael Hu

CMO

MD, MS pharmacology, Fudan Univ. Medical School

20+ years experience in clinical development and medical affairs; Former Head of Medical at Bayer (China)

Qi Shao

SVP & CFO

BS economics Southeastern Univ.  MS Finance Shanghai Univ.

10+ years experience in finance, auditing, taxation, investment and M&A at BASF and Continental 

Hangzhou LV

SVP Mktg. & Sales

BS Lanzhou Univ., MBA Nanjing Univ.

20+ years of marketing, sales, and market access experience at Pfizer (China) and Novartis (China)

Cheryl Tan

Global Head of Intl. Businesses

MBA, London School of Economics; Executive Program with Harvard, IMD, INSEAD

25+years of commercial, general management  experience across Regional (APAC) & Global emerging markets at Sanofi, Abbott and GSK